19 August 2019 in Cancer Imaging
The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter has emerged as a favorable independent prognostic and predictive biomarker in glioma. This study aimed to build a radiomics signature based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for noninvasive measurement of the MGMT promoter methylation status in glioma. One hundred and seven pathology-confirmed primary diffuse glioma patients were retrospectively included and randomly assigned to the primary (n = 71) or validation cohort (n = 36). The MGMT promoter methylation status was measured by pyrosequencing. A total of 1561 radiomics features were extracted from the three-dimensional region of interest (ROI) on the standard uptake value (SUV) maps that were generated from the original 18F-FDG PET data. A radiomics signature, a clinical signature and a fusion signature that combined the clinical and radiomics features together were generated. The performance of the three signatures was evaluated by receiver operating characteristic (ROC) curve analysis, and the patient prognosis was stratified based on the MGMT promoter methylation status and the signature with the best performance. Five radiomics features were selected to construct the radiomics signature, and displayed the best performance with area under the receiver operating characteristic (ROC) curve (AUC) reaching 0.94 and 0.86 in the primary and validation cohorts, respectively, which outweigh the performances of clinical signature and fusion signature. With a median follow-up time of 32.4 months, the radiomics signature stratified the glioma patients into two risk groups with significantly different prognoses (p = 0.04). 18F-FDG-PET-based radiomics is a promising approach for preoperatively evaluating the MGMT promoter methylation status in glioma and predicting the prognosis of glioma patients noninvasively.
10 May 2022 in Journal of Healthcare Engineering
Accurate preoperative glioma grading is essential for clinical decision-making and prognostic evaluation. Multiparametric magnetic resonance imaging (mpMRI) serves as an important diagnostic tool for glioma patients due to its superior performance in describing noninvasively the contextual information in tumor tissues. Previous studies achieved promising glioma grading results with mpMRI data utilizing a convolutional neural network (CNN)-based method. However, these studies have not fully exploited and effectively fused the rich tumor contextual information provided in the magnetic resonance (MR) images acquired with different imaging parameters. In this paper, a novel graph convolutional network (GCN)-based mpMRI information fusion module (named MMIF-GCN) is proposed to comprehensively fuse the tumor grading relevant information in mpMRI. Specifically, a graph is constructed according to the characteristics of mpMRI data. The vertices are defined as the glioma grading features of different slices extracted by the CNN, and the edges reflect the distances between the slices in a 3D volume. The proposed method updates the information in each vertex considering the interaction between adjacent vertices. The final glioma grading is conducted by combining the fused information in all vertices. The proposed MMIF-GCN module can introduce an additional nonlinear representation learning step in the process of mpMRI information fusion while maintaining the positional relationship between adjacent slices. Experiments were conducted on two datasets, that is, a public dataset (named BraTS2020) and a private one (named GliomaHPPH2018). The results indicate that the proposed method can effectively fuse the grading information provided in mpMRI data for better glioma grading performance.